8-K: Stereotaxis Q3 2025: Robotic System Orders & FDA Clearance

Stereotaxis reports Q3 2025 financial results, highlighting new robotic system orders, FDA clearance for GenesisX, and progress in its catheter portfolio.

Summary

• Total revenue for the third quarter of 2025 was $7.5 million, compared to $9.2 million in the prior year third quarter.
• System revenue was $1.9 million, reflecting partial revenue recognition on one capital system, down from $4.4 million in Q3 2024.
• Recurring revenue increased to $5.6 million, up from $4.8 million in Q3 2024, driven by Map-iT, MAGiC, and MAGiC Sweep.
• Gross margin for Q3 2025 was 55% of revenue, with recurring revenue gross margin at 67% and system gross margin at 19%.
• Operating expenses in Q3 2025 were $10.7 million, including $4.1 million in non-cash charges.
• Adjusted operating expenses (excluding non-cash charges) were $6.6 million, a decrease from $7.2 million in Q3 2024.
• Operating loss was ($6.6) million and net loss was ($6.5) million in Q3 2025, compared to ($6.3) million and ($6.2) million, respectively, in Q3 2024.
• Adjusted operating loss and adjusted net loss (excluding non-cash charges) were ($2.5) million and ($2.4) million, respectively, an improvement from ($3.1) million and ($3.0) million in Q3 2024.
• Negative free cash flow for Q3 2025 was ($4.2) million, consistent with the previous year.
• Cash and cash equivalents stood at $10.5 million as of September 30, 2025, with no debt.
• Two Genesis robotic systems were ordered by European hospitals since the last quarterly call, establishing new robotic programs.
• U.S. FDA regulatory clearance for the GenesisX robotic system was announced.
• European CE Mark receipt and FDA submission for Synchrony digital cath lab technology were recently announced.
• MAGiC Sweep generated over $300,000 in revenue within the first two months of launch following recent FDA clearance.
• A collaboration with CardioFocus was announced to advance the first robotically-navigated pulsed-field ablation electrophysiology catheter solution.

Sentiment

Score: 7

Explanation: While total revenue and system revenue declined year-over-year, the company demonstrated strong progress in recurring revenue, new product launches (MAGiC, MAGiC Sweep), significant regulatory clearances (GenesisX FDA, Synchrony CE Mark), and new system orders. The improved adjusted losses and positive future outlook, supported by an upcoming capital infusion, indicate a positive trajectory despite current losses.

Positives

• Secured two new Genesis robotic system orders from European hospitals, establishing entirely new robotic programs.
• Recurring revenue increased to $5.6 million in Q3 2025 from $4.8 million in Q3 2024, demonstrating positive momentum.
• Successful early launches of MAGiC and MAGiC Sweep, with MAGiC Sweep generating over $300,000 in revenue within two months of FDA clearance.
• Received U.S. FDA regulatory clearance for the GenesisX robotic system.
• Achieved European CE Mark receipt and submitted for FDA clearance for Synchrony digital cath lab technology.
• Announced a collaboration with CardioFocus to develop the first robotically-navigated pulsed-field ablation electrophysiology catheter solution.
• Adjusted operating loss and adjusted net loss improved year-over-year, indicating better cost management excluding non-cash charges.
• Maintained a strong cash balance of $10.5 million with no debt, expected to increase to $14.5 million with upcoming financing.

Negatives

• Total revenue decreased to $7.5 million in Q3 2025 from $9.2 million in Q3 2024.
• System revenue significantly decreased to $1.9 million in Q3 2025 from $4.4 million in Q3 2024.
• Operating loss increased to ($6.6) million in Q3 2025 from ($6.3) million in Q3 2024.
• Net loss increased to ($6.5) million in Q3 2025 from ($6.2) million in Q3 2024.
• Gross margins remain impacted by fixed overhead allocated over low production levels.
• Negative free cash flow of ($4.2) million, consistent with the prior year.

Risks

• Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially.
• Ability to manage expenses at sustainable levels.
• Acceptance of products in the marketplace.
• Effect of global economic conditions, including tariffs, on the ability and willingness of customers to purchase its technology.
• Competitive factors in the surgical robotics and medical device markets.
• Changes resulting from healthcare policy.
• Dependence upon third-party vendors for components and services.
• Timing of regulatory approvals for new products and technologies.
• Impact of pandemics or other disasters on operations and market demand.
• Uncertainty regarding the benefits expected from the recent acquisition of APT.
• No assurance that revenue related to purchase orders and other commitments will be recognized due to contingencies, revisions, modifications, delays, or cancellations.

Future Outlook

Stereotaxis expects revenue in the fourth quarter of 2025 to exceed $9 million, with system revenue of approximately $3 million and recurring revenue greater than $6 million. This supports annual revenue growth for the current year of over 20%, in-line with previous guidance of double-digit revenue growth for the full year 2025. Sustained growth of both system and recurring revenue is expected in 2026, with quarterly revenue projected to surpass an average of $10 million per quarter. The company's balance sheet, including an additional $4 million in proceeds from equity financing this month, is expected to fund its transformative product ecosystem, commercialization, and achievement of profitability.

Management Comments

• "We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones." David Fischel, Chairman and CEO.
• "This is an exciting milestone-rich period in which we are demonstrating the tangible reality and initial commercial impact of our comprehensive innovation strategy." David Fischel, Chairman and CEO.
• "We are beginning to build a clinically and commercially impactful catheter portfolio."

Industry Context

Stereotaxis operates in the dynamic and growing surgical robotics and minimally invasive endovascular intervention market. The company's strategic focus on developing and commercializing advanced robotic systems (GenesisX), digital cath lab technology (Synchrony), and a proprietary catheter portfolio (MAGiC, MAGiC Sweep, and the CardioFocus collaboration for pulsed-field ablation) aligns with broader industry trends towards enhanced precision, improved patient outcomes, and expanded access to complex interventional therapies, particularly in electrophysiology. The increasing adoption of robotic platforms in healthcare underscores the relevance of Stereotaxis's innovation strategy.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for future growth and profitability driven by new product launches, regulatory approvals, and increased system adoption. Current losses and negative free cash flow remain a concern, but adjusted metrics show improvement. The upcoming capital raise strengthens liquidity.
• Customers (Hospitals/Physicians): Access to new robotic systems (GenesisX) and advanced catheter technologies (MAGiC, MAGiC Sweep, Synchrony), potentially enhancing patient care and procedural efficiency in minimally invasive endovascular interventions.
• Employees: Continued focus on product development and commercialization suggests ongoing investment in the company's workforce, particularly in R&D and sales.

Next Steps

• Advance multiple regulatory reviews for new electrophysiology and vascular catheters.
• Advance a pipeline of catheter innovations to contribute to commercial results in the short and medium term.
• Receive an additional $4 million in proceeds from the equity financing announced in July during November 2025.
• Host a conference call and webcast on November 11, 2025, at 4:30 p.m. Eastern Time to discuss the results.

Key Dates

Recommendation

While Stereotaxis reported a decline in total revenue and system sales for Q3 2025, the underlying operational progress is notable. Recurring revenue growth, successful early product launches (MAGiC Sweep), and critical regulatory clearances (GenesisX FDA, Synchrony CE Mark) demonstrate strong execution on its innovation strategy. The company's forward-looking guidance for double-digit revenue growth in 2025 and sustained growth in 2026, coupled with an improved adjusted loss and a strengthened cash position from an upcoming capital raise, suggests a positive trajectory. However, the company remains unprofitable with negative free cash flow, and system sales can be lumpy. The stock is a 'hold' as the company executes on its strategy, with potential for future upside if commercial traction accelerates and profitability improves, but current financial performance still carries risk.

Keywords

Surgical Robotics, Endovascular Intervention, Electrophysiology, Minimally Invasive Surgery, Medical Devices, FDA Clearance, CE Mark, Robotic Catheter, Ablation, Digital Cath Lab, STXS, Stereotaxis